Table 1. Clinical trials on targetable driver mutations in patients with NSCLC.

ALK: anaplastic lymphoma kinase; BID: twice daily; EGFR: epidermal growth factor receptor; KRAS: Kirsten rat sarcoma viral oncogene homolog; NSCLC: non-small cell lung cancer; OD: once daily; RET: rearranged during transfection; ROS1: c-ROS oncogene

Trial name, phase	Driver mutations in patient population (n)	Drug/dose	Response rate (%)
ARROW, phase I/II [11]	RET fusion-positive advanced or metastatic NSCLC and ECOG PS 0-2 (n = 233)	Pralsetinib, 400 mg OD	Overall response: 61% (95% CI = 50 to 71)
NCI-MATCH, ongoing trial with open sub-protocols [12]	ALK (n = 5) or ROS1 rearrangements (n = 4)	Crizotinib, 250 mg BID, 28-day cycle	Sub-protocol F (ALK): 50% (90% CI = 9.8 to 90.2); sub-protocol G (ROS1): 25% (90% CI = 1.3 to 75.1)
FLAURA, Phase III [13]	EGFR-positive advanced NSCLC (n = 556)	Osimertinib (80 mg OD) or either gefitinib (250 mg OD) or erlotinib (150 mg OD)	Median overall survival: osimertinib group: 38.6 months (95% CI = 34.5 to 41.8); comparator group: 31.8 months (95% CI = 26.6 to 36.0)
CROWN, Phase III [14]	ALK-positive advanced NSCLC (n = 296)	Lorlatinib, 100 mg OD or crizotinib 250 mg BID, 28 days cycle	Objective response: lorlatinib group: 76% (95% CI = 68 to 83); crizotinib group: 58% (95% CI = 49 to 66)
Phase II [15]	KRAS p.G12C-mutated advanced NSCLC (n = 126)	Sotorasib, 960 mg OD	Objective response: 37.1% (95% CI = 28.6 to 46.2)